Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-014027
Filing Date
2017-08-08
Accepted
2017-08-08 11:29:38
Documents
51
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q atrn20170630_10q.htm 10-Q 553587
2 EXHIBIT 31.1 ex31-1.htm EX-31.1 22655
3 EXHIBIT 31.2 ex31-2.htm EX-31.2 22821
4 EXHIBIT 32.1 ex32-1.htm EX-32.1 8786
  Complete submission text file 0001437749-17-014027.txt   3697359

Data Files

Seq Description Document Type Size
5 EXHIBIT 101.INS ptix-20170630.xml EX-101.INS 729415
6 EXHIBIT 101.SCH ptix-20170630.xsd EX-101.SCH 41567
7 EXHIBIT 101.CAL ptix-20170630_cal.xml EX-101.CAL 24572
8 EXHIBIT 101.DEF ptix-20170630_def.xml EX-101.DEF 318623
9 EXHIBIT 101.LAB ptix-20170630_lab.xml EX-101.LAB 244517
10 EXHIBIT 101.PRE ptix-20170630_pre.xml EX-101.PRE 327064
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51353 | Film No.: 171013750
SIC: 7389 Services-Business Services, NEC